Insider Selling: Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Major Shareholder Sells $122,018.76 in Stock

Conduit Pharmaceuticals Inc. (NASDAQ:CDTGet Free Report) major shareholder Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $0.12, for a total transaction of $122,018.76. Following the completion of the transaction, the insider now owns 11,483,177 shares of the company’s stock, valued at $1,377,981.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ltd Nirland also recently made the following trade(s):

  • On Wednesday, October 2nd, Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.10, for a total value of $33,317.70.

Conduit Pharmaceuticals Stock Performance

Shares of CDT opened at $0.10 on Friday. Conduit Pharmaceuticals Inc. has a 52 week low of $0.10 and a 52 week high of $7.83. The business’s fifty day moving average price is $0.15 and its two-hundred day moving average price is $1.56.

Conduit Pharmaceuticals (NASDAQ:CDTGet Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Berenberg Bank raised Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.

Get Our Latest Stock Analysis on Conduit Pharmaceuticals

Conduit Pharmaceuticals Company Profile

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Recommended Stories

Insider Buying and Selling by Quarter for Conduit Pharmaceuticals (NASDAQ:CDT)

Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.